Impact of multiple-dose versus single-dose inhaler devices on COPD patients' persistence with long-acting beta(2)-agonists: A dispensing database analysis

Job F. M. van Boven*, Joost J. van Raaij, Ruben van der Galiën, Maarten J. Postma, Thys van der Molen, P. N. Richard Dekhuijzen, Stefan Vegter

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

11 Citations (Scopus)
153 Downloads (Pure)

Abstract

BACKGROUND: With a growing availability of different devices and types of medication, additional evidence is required to assist clinicians in prescribing the optimal medication in relation to chronic obstructive pulmonary disease (COPD) patients' persistence with long-acting beta(2)-agonists (LABAs).

AIMS: To assess the impact of the type of inhaler device (multiple-dose versus single-dose inhalers) on 1-year persistence and switching patterns with LABAs.

METHODS: A retrospective observational cohort study was performed comparing a cohort of patients initiating multiple-dose inhalers and a cohort initiating single-dose inhalers. The study population consisted of long-acting bronchodilator naive COPD patients, initiating inhalation therapy with mono-LABAs (formoterol, indacaterol or salmeterol). Analyses were performed using pharmacy dispensing data from 1994 to 2012, obtained from the IADB.nl database. Study outcomes were 1-year persistence and switching patterns. Results were adjusted for initial prescriber, initial medication, dosing regimen and relevant comorbidities.

RESULTS: In all, 575 patients initiating LABAs were included in the final study cohort. Among them, 475 (83%) initiated a multiple-dose inhaler and 100 (17%) a single-dose inhaler. Further, 269 (47%) initiated formoterol, 9 (2%) indacaterol and 297 (52%) salmeterol. There was no significant difference in persistence between users of multiple-dose or single-dose inhalers (hazard ratio: 0.98, 95% confidence interval: 0.76-1.26, P = 0.99). Over 80% re-started or switched medication.

CONCLUSIONS: There seems no impact of inhaler device (multiple-dose versus single-dose inhalers) on COPD patients' persistence with LABAs. Over 80% of patients who initially seemed to discontinue LABAs, re-started their initial medication or switched inhalers or medication within 1 year.

Original languageEnglish
Article number14069
Number of pages6
JournalPrimary Care Respiratory Medicine
Volume24
DOIs
Publication statusPublished - 2-Oct-2014

Keywords

  • OBSTRUCTIVE PULMONARY-DISEASE
  • MEDICATION NONADHERENCE
  • INHALATION TECHNIQUE
  • ECONOMIC-IMPACT
  • ADMIT SERIES
  • ADHERENCE
  • THERAPY
  • ASTHMA
  • POPULATION
  • OUTCOMES

Cite this